v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.

Key Inclusion Criteria:

• Has stable chronic heart failure with reduced ejection fraction
• Has adequate acoustic windows for echocardiography

Key Exclusion Criteria:

• Any significant structural cardiac abnormalities on Screening TTE
• At Screening, symptomatic hypotension or hypertension or bradycardia.
• Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, vasodilators [e.g., nesiritide], diuretics) or routinely scheduled ultrafiltration.
• Presence of protocol specified laboratory abnormalities at Screening.